<DOC>
	<DOC>NCT00338936</DOC>
	<brief_summary>This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.</brief_summary>
	<brief_title>Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients who successfully complete the core study (Protocol 1303) Outpatients Presence of crucial protocol violation in Protocol 1303 Patients who experienced any adverse events considered serious and drug related in Protocol 1303.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Hydrochlorothiazide</keyword>
</DOC>